Vitrolife withdraws its offer for MediCult

With reference to its voluntary exchange offer of 3 February 2009 (as extended) to purchase the shares in MediCult a/s (OSE: MEC), Vitrolife hereby announce that as of the expiry of the offer on 27 March 2009 at 17:30 CET, the level of acceptances received had not reached 90 per cent of the shares in MediCult a/s. As a result, the conditions for the offer have not been fulfilled and the offer has been withdrawn.

Contact persons at Vitrolife with respect to the Offer:

Patrik Tigerschiöld, Chairman of the Board tel. +46 707 77 71 90
Dr. Magnus Nilsson, CEO tel. +46 31 721 80 61

About Us

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife has about 400 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.


Documents & Links